Chapter 13: Current findings from prophylactic HPV vaccine trials
- 21 August 2006
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 24, S114-S121
- https://doi.org/10.1016/j.vaccine.2006.06.014
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Vaccine, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineVaccine, 2004
- Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccineVaccine, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- DETECTION WITH THE POLYMERASE CHAIN REACTION OF HUMAN PAPILLOMAVIRUS DNA IN CONDYLOMATA ACUMINATA TREATED WITH CO2LASER AND MICROWAVEInternational Journal of Dermatology, 1995